Medicare AdvantagePrior AuthMedium impact
MA06.001f, Apheresis Therapy
Independence Blue Cross·Hematology, Oncology, Nephrology +2 more·Medical Policy
Effective date
Mar 17, 2025
We identified it
Jun 19, 2026
Summary
Policy MA06.001f on Apheresis Therapy has been updated with changes to medical necessity criteria, medical coding, and general guidelines/informational content. This recent update (effective 03/17/2025) requires the billing team to review and implement new requirements for apheresis therapy authorization and billing on Medicare Advantage plans.
Action Required
By 03/17/2025: Billing team must obtain and review the complete policy text from https://medpolicy.ibx.com/ibc/ma/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=03&FilterField2=MPSiteActivityLogYear&FilterValue2=2025 to identify specific billing codes, medical necessity criteria, and documentation requirements for apheresis therapy. Update billing system rules, prior authorization workflows, and provider encounter forms to reflect new medical necessity criteria and coding guidelines. Communicate changes to providers and clinical staff. Ensure all apheresis therapy claims submitted after 03/17/2025 comply with updated medical necessity requirements to avoid claim denials.